Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1B OPEN-LABEL THREE-ARM MULTI-CENTER STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF PF-05212384 (PI3K/MTOR INHIBITOR) IN COMBINATION WITH OTHER ANTI-TUMOR AGENTS

NCT01920061 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01920061
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01920061 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1B OPEN-LABEL THREE-ARM MULTI-CENTER STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF PF-05212384 (PI3K/MTOR INHIBITOR) IN COMBINATION WITH OTHER ANTI-TUMOR AGENTS
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
September 10, 2013
Completion date
January 8, 2020
Enrollment
110 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasm